Kotaro Shikano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kotaro Shikano has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Kaichi Kaneko
Division of Rheumatology, Department of Internal Medicine Toho University Sakura Medical Center Sakura Chiba Japan
1 shared publication - Karin Furukawa
Department of Internal Medicine, Toho University Graduate School of Medicine, Tokyo, Japan
1 shared publication - Mai Kawazoe
Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine , Tokyo 143-8541
1 shared publication - Takahiko Sugihara
Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
1 shared publication - Toshihiro Nanki
Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
1 shared publication
Latest Publications
- 1 June 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (9) , 927-933
Long-Term Effectiveness and Safety of Denosumab for Osteoporosis in Patients With Rheumatic Diseases
Objective: The long-term effectiveness of denosumab, an antireceptor activator of nuclear factor-κB ligand monoclonal antibody, for increasing bone mineral density (BMD) and reducing fracture risk in postmenopausal women with osteoporosis (OP) has been demonstrated; however, the long-term effectiveness and safety in patients with rheumatic diseases (RDs) remain unclear. Therefore, the present study investigated the long-term effectiveness and safety of denosumab for OP in patients with RDs. Methods: This retrospective study included patients who received denosumab between August 2013 and August 2022. We evaluated BMD at the lumbar spine for up to 7 years and at the femur for up to 3 years. The effects of glucocorticoid (GC) usage, age, and renal function on BMD in patients receiving denosumab were assessed. The retention rate and adverse events were also evaluated. Results: One hundred sixty-five patients with RDs were enrolled (median age 66.5 years, 92.1% female, 68.5% receiving GC therapy). Lumbar spine BMD significantly increased over 7 years (P < 0.001), whereas femoral neck, trochanter, and total hip BMD significantly increased for up to 3 years (P < 0.001). Lumbar spine BMD significantly increased regardless of GC dose, age, or renal dysfunction. The retention rate of denosumab at 7 years was 68.1%. The most common serious adverse event was infection. Two cases of osteonecrosis of the jaw and 10 new fractures were observed during treatment with denosumab. Conclusion: The present study suggests that the long-term use of denosumab is an effective and generally safe option for increasing BMD in patients with RDs.
- 1 June 2025
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 52 (9) , 927-933
Long-Term Effectiveness and Safety of Denosumab for Osteoporosis in Patients With Rheumatic Diseases
Objective: The long-term effectiveness of denosumab, an antireceptor activator of nuclear factor-κB ligand monoclonal antibody, for increasing bone mineral density (BMD) and reducing fracture risk in postmenopausal women with osteoporosis (OP) has been demonstrated; however, the long-term effectiveness and safety in patients with rheumatic diseases (RDs) remain unclear. Therefore, the present study investigated the long-term effectiveness and safety of denosumab for OP in patients with RDs. Methods: This retrospective study included patients who received denosumab between August 2013 and August 2022. We evaluated BMD at the lumbar spine for up to 7 years and at the femur for up to 3 years. The effects of glucocorticoid (GC) usage, age, and renal function on BMD in patients receiving denosumab were assessed. The retention rate and adverse events were also evaluated. Results: One hundred sixty-five patients with RDs were enrolled (median age 66.5 years, 92.1% female, 68.5% receiving GC therapy). Lumbar spine BMD significantly increased over 7 years (P < 0.001), whereas femoral neck, trochanter, and total hip BMD significantly increased for up to 3 years (P < 0.001). Lumbar spine BMD significantly increased regardless of GC dose, age, or renal dysfunction. The retention rate of denosumab at 7 years was 68.1%. The most common serious adverse event was infection. Two cases of osteonecrosis of the jaw and 10 new fractures were observed during treatment with denosumab. Conclusion: The present study suggests that the long-term use of denosumab is an effective and generally safe option for increasing BMD in patients with RDs.